Gamal Esmat

13.7k total citations
288 papers, 5.6k citations indexed

About

Gamal Esmat is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Gamal Esmat has authored 288 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 224 papers in Hepatology, 198 papers in Epidemiology and 29 papers in Molecular Biology. Recurrent topics in Gamal Esmat's work include Hepatitis C virus research (202 papers), Liver Disease Diagnosis and Treatment (175 papers) and Hepatitis B Virus Studies (107 papers). Gamal Esmat is often cited by papers focused on Hepatitis C virus research (202 papers), Liver Disease Diagnosis and Treatment (175 papers) and Hepatitis B Virus Studies (107 papers). Gamal Esmat collaborates with scholars based in Egypt, United States and France. Gamal Esmat's co-authors include Tamer Elbaz, Mohamed El‐Kassas, Wafaa Elakel, Ahmed Ihab Abdelaziz, G. Thomas Strickland, Maissa El Raziky, M.F. Abdel-Wahab, Wahid Doss, Imam Waked and Aisha Elsharkawy and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Gamal Esmat

274 papers receiving 5.4k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Gamal Esmat 3.4k 3.3k 696 577 516 288 5.6k
Flair José Carrilho 4.4k 1.3× 4.7k 1.4× 618 0.9× 160 0.3× 321 0.6× 302 7.3k
Nabiel Mikhail 1.9k 0.5× 1.5k 0.5× 342 0.5× 225 0.4× 179 0.3× 80 3.6k
Sombat Treeprasertsuk 1.3k 0.4× 2.0k 0.6× 241 0.3× 436 0.8× 140 0.3× 190 4.1k
Tsung‐Hui Hu 4.4k 1.3× 4.3k 1.3× 1.1k 1.6× 63 0.1× 658 1.3× 339 7.4k
Imam Waked 2.4k 0.7× 2.3k 0.7× 555 0.8× 48 0.1× 376 0.7× 134 3.5k
W. Thomas London 2.0k 0.6× 2.5k 0.8× 839 1.2× 68 0.1× 358 0.7× 102 4.3k
Sheng‐Nan Lu 9.4k 2.8× 9.5k 2.9× 879 1.3× 81 0.1× 805 1.6× 379 12.3k
Jidong Jia 4.2k 1.2× 4.3k 1.3× 866 1.2× 41 0.1× 212 0.4× 315 6.4k
Douglas T. Dieterich 6.9k 2.0× 7.0k 2.1× 221 0.3× 140 0.2× 87 0.2× 258 9.3k
Robert Flisiak 5.4k 1.6× 5.4k 1.7× 828 1.2× 40 0.1× 109 0.2× 364 7.8k

Countries citing papers authored by Gamal Esmat

Since Specialization
Citations

This map shows the geographic impact of Gamal Esmat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gamal Esmat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gamal Esmat more than expected).

Fields of papers citing papers by Gamal Esmat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gamal Esmat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gamal Esmat. The network helps show where Gamal Esmat may publish in the future.

Co-authorship network of co-authors of Gamal Esmat

This figure shows the co-authorship network connecting the top 25 collaborators of Gamal Esmat. A scholar is included among the top collaborators of Gamal Esmat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gamal Esmat. Gamal Esmat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Assal, R.A., R.A. Youness, Karim Adel Hosny, et al.. (2024). OncomiR-181a promotes carcinogenesis by repressing the extracellular matrix proteoglycan decorin in hepatocellular carcinoma. BMC Gastroenterology. 24(1). 337–337. 2 indexed citations
2.
Tawheed, Ahmed, Mohamed El‐Kassas, Amr El Fouly, & Gamal Esmat. (2023). Predictors of Treatment Failure with Sofosbuvir/Daclatasvir Regimen for 12 Weeks in Patients with Chronic HCV in Egypt. International Journal of TROPICAL DISEASE & Health. 57–64. 1 indexed citations
3.
El‐Kassas, Mohamed, Mohamed Hassany, Gamal Esmat, et al.. (2023). A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C. Journal of Hepatology. 79(2). 314–320. 9 indexed citations
4.
Ezzat, Sameera, Ivane Gamkrelidze, Asmaa Gomaa, et al.. (2023). Impacts of the Egyptian national screening and treatment programme for viral hepatitis C: A cost‐effectiveness model. Liver International. 43(7). 1417–1426. 6 indexed citations
5.
Younossi, Zobair M., Yusuf Yılmaz, Mohamed El‐Kassas, et al.. (2022). The impact of the COVID‐19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry. Hepatology Communications. 6(10). 2860–2866. 3 indexed citations
6.
Cordie, Ahmed, Rosmawati Mohamed, Jeffrey V. Lazarus, et al.. (2021). COVID-19 vaccine acceptance and its associated factors among people living with HIV (PLHIV) in the Middle East and North Africa (MENA) region: a cross-sectional multi-centre study. HIV Medicine. 22. 208–209. 1 indexed citations
7.
Abdel‐Razek, Wael, Mohamed Hassany, Manal H. El‐Sayed, et al.. (2019). Hepatitis C Virus in Egypt: Interim Report From the World’s Largest National Program. Clinical Liver Disease. 14(6). 203–206. 18 indexed citations
8.
Gamil, Mohamed, Mohamed Alboraie, Aisha Elsharkawy, et al.. (2018). Novel scores combining AFP with non‐invasive markers for prediction of liver fibrosis in chronic hepatitis C patients. Journal of Medical Virology. 90(6). 1080–1086. 23 indexed citations
9.
Yosry, Ayman, Eman Medhat, Naglaa Zayed, et al.. (2018). Efficacy and safety of sofosbuvir‐based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience. Journal of Medical Virology. 91(4). 668–676. 2 indexed citations
10.
Elsharkawy, Aisha, et al.. (2017). Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Review of Gastroenterology & Hepatology. 11(8). 773–778. 30 indexed citations
11.
Assal, R.A., et al.. (2016). miR-34a: Multiple Opposing Targets and One Destiny in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology. 4(4). 300–305. 5 indexed citations
12.
Elsharkawy, Aisha, et al.. (2016). Noninvasive Assessment of Liver Fibrosis in Egyptian Children with Chronic Liver Diseases.. Current Pediatric Research. 20(1). 0. 9 indexed citations
13.
Saad, Yasmin, Maissa El Raziky, Naglaa Zayed, et al.. (2013). Hepatitis C genotype 4 with normal transaminases: Correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients. Clinics and Research in Hepatology and Gastroenterology. 37(5). 479–484. 7 indexed citations
14.
15.
Obach, Dorothée, Sylvie Deuffic‐Burban, Gamal Esmat, et al.. (2013). 885 IMMEDIATE vs. DELAYED TREATMENT IN GENOTYPE 4-HCV INFECTED PATIENTS IN A LIMITED RESOURCES COUNTRY: A COST-EFFECTIVENESS ANALYSIS IN EGYPT (ANRS 12215). Journal of Hepatology. 58. S364–S364. 2 indexed citations
16.
Yosry, Ayman, et al.. (2013). Transient Elastography can Predict the Risk of Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C. Journal of Gastroenterology and Hepatology Research. 2(7). 687–691.
17.
Mabrouk, Mahasen, Wahid Doss, Naglaa Zayed, Shimaa Afify, & Gamal Esmat. (2013). Impact of Serum Alpha-fetoprotein Levels on the Response to Antiviral Therapy in Egyptian Patients with Chronic Hepatitis C. Journal of Gastroenterology and Hepatology Research. 2(5). 597–601. 3 indexed citations
18.
Mohamed, M.K., et al.. (2010). Relationship between HCV infection and Insulin resistance in non-obese non- diabetic patients. The Egyptian Journal of Hospital Medicine. 41(1). 540–550.
19.
Rekacewicz, Claire, Sherif A. El‐Kafrawy, Mohamed Abdel-Hamid, et al.. (2008). Symptomatic Acute Hepatitis C in Egypt: Diagnosis, Spontaneous Viral Clearance, and Delayed Treatment with 12 Weeks of Pegylated Interferon Alfa-2a. PLoS ONE. 3(12). e4085–e4085. 16 indexed citations
20.
Esmat, Gamal, Claire Rekacewicz, Khaled Zalata, et al.. (2007). Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.. PubMed. 12(5). 797–803. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Flair José Carrilho Breakdown of academic impact, for papers by Nabiel Mikhail Breakdown of academic impact, for papers by Sombat Treeprasertsuk Breakdown of academic impact, for papers by Tsung‐Hui Hu Breakdown of academic impact, for papers by Imam Waked Breakdown of academic impact, for papers by W. Thomas London Breakdown of academic impact, for papers by Sheng‐Nan Lu Breakdown of academic impact, for papers by Jidong Jia Breakdown of academic impact, for papers by Douglas T. Dieterich Breakdown of academic impact, for papers by Robert Flisiak
Rankless by CCL
2026